Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Monitorización hospitalaria de heparina no fraccionada

15 de septiembre de 2026 actualizado por: Benjamin Tillman, Vanderbilt University Medical Center

Unfractionated heparin (UFH) is the most widely used intravenous (IV) anticoagulant for treating and preventing thromboembolic disease (e.g., blood clots ). UFH must be closely monitored and adjusted in the hospital. There are two assays used to monitor UFH: 1) the activated partial thromboplastin time (PTT) and 2) the chromogenic anti-factor Xa assay (anti-Xa). This study aims to compare PTT and anti-Xa methods for monitoring UFH in a pragmatic, randomized controlled trial to determine which helps patients reach a therapeutic anticoagulation range faster.

Descripción general del estudio

Estado

Terminado

Descripción detallada

Unfractionated heparin (UFH) is the most widely used intravenous (IV) anticoagulant for the treatment and prevention of thromboembolic disease (e.g., blood clots ). When administered by intravenous injection, the onset of action is immediate. Indications for use of UFH include venous thromboembolism, acute coronary syndrome, and acute ischemic stroke. UFH is used to prevent thrombosis in the setting of arrhythmias, extracorporeal membrane oxygenation (ECMO), cardiopulmonary bypass (CPB), and endovascular procedures. The unpredictable pharmacokinetics of UFH and interpatient variability result in a narrow therapeutic index restricting its use to the hospital setting with close monitoring and adjustments.

Two validated assays exist and are in use at the VUMC adult hospital for the monitoring of unfractionated heparin: 1) the activated partial thromboplastin time (PTT) and 2) the chromogenic anti-factor Xa assay (anti-Xa). At VUMC, the PTT protocol is managed by nursing; the anti-Xa protocol is managed by clinical pharmacy. Both are clinically acceptable methods for titration and adjustment of unfractionated heparin. Assessing the therapeutic effect of unfractionated heparin is most often performed with the PTT, which requires institutional calibration to a specific heparin level to account for the variable PTT responses with different commercial reagents and laboratory instruments. The PTT can be influenced by various elements during sample processing, laboratory analysis, and patient biological factors that may cause it to be an inaccurate indication of the degree of anticoagulation. This can lead to patients not getting the correct heparin dosing for their clinical needs.

The anti-Xa assay is another method of measuring the degree of therapeutic effect of heparin. In routine clinical practice the anti-Xa is not as widely available and less familiar among many providers. This assay can be impacted by variability in sample collection and processing and laboratory analysis. Compared to the PTT assay, however, it is much less influenced by patient-specific biological factors. This may help improve heparin monitoring and titration to ensure patients receive therapeutic levels of anticoagulation and do not get too much or too little heparin. However, large studies using anti-Xa for management of heparin in the treatment of venous thromboembolism have not been performed.

PTT and anti-Xa heparin monitoring protocols have not been compared in a prospective, randomized setting. The study team will conduct a pragmatic, randomized clinical trial comparing the effectiveness of both methods for optimal monitoring of intravenous unfractionated heparin for systemic anticoagulation in hospitalized adult patients.

Tipo de estudio

Intervencionista

Inscripción (Actual)

700

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37232
        • Vanderbilt University Medical Center

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Patients at Vanderbilt University Hospital age 18 years and older who are admitted as observation or inpatients for whom intravenous unfractionated heparin (monitored via the PTT nurse-managed protocol) is ordered.
  • Baseline PTT value is ≥0 and ≤ 36.0 seconds
  • Baseline heparin level anti-Xa assay value is ≥0 and ≤0.3

Exclusion Criteria:

  • Indication for anticoagulation is extracorporeal membrane oxygenation or cerebrovascular ischemic event.
  • Provider determines patient is not appropriate for the study.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Investigación de servicios de salud
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Active Comparator: PTT protocol

Patients randomized to this arm will be monitored using the nurse-managed PTT guided protocol. This includes patients on both high- and low-dose heparin protocols.

Patients will be monitored using the nurse-managed PTT protocol.

Comparador activo: Active Comparator: anti-Xa protocol

Patients randomized to this arm will be monitored using the pharmacy-managed anti-Xa protocol. This includes patients on both high- and low-dose heparin protocols.

Patients will be monitored using the pharmacy-managed anti-Xa protocol.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Time to therapeutic anticoagulation range
Periodo de tiempo: Randomization to hospital discharge at approximately 5-7 days post-randomization

Time to reach therapeutic anticoagulation range by coagulation assay

Randomization to hospital discharge at approximately 5-7 days post-randomization

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Measurements in therapeutic anticoagulation range
Periodo de tiempo: Randomization to hospital discharge at approximately 5-7 days post-randomization

Percent of measurements in therapeutic range per coagulation assay, as defined by assay protocol

Randomization to hospital discharge at approximately 5-7 days post-randomization
Coagulation laboratory measurements
Periodo de tiempo: Randomization to hospital discharge at approximately 5-7 days post-randomization

The number of coagulation laboratory measurements for overall in-hospital coagulation time.

Randomization to hospital discharge at approximately 5-7 days post-randomization
Heparin rate changes
Periodo de tiempo: Randomization to hospital discharge at approximately 5-7 days post-randomization

Total number of heparin rate changes for overall in-hospital coagulation time

Randomization to hospital discharge at approximately 5-7 days post-randomization
New thrombotic events
Periodo de tiempo: Randomization to hospital discharge at approximately 5-7 days post-randomization and for 24 hours after anticoagulation cessation.

Incidence of new thrombotic events on anticoagulation or within 24 hours of anticoagulation cessation

Randomization to hospital discharge at approximately 5-7 days post-randomization and for 24 hours after anticoagulation cessation.
New clinically relevant bleeding events
Periodo de tiempo: Randomization to 48 hours after anticoagulation cessation, approximately 5-7 days post-randomization

Incidence of clinically relevant bleeding adverse events on anticoagulation or within 48 hours of anticoagulation cessation, defined as: fatal bleeding, or overt events causing a decline in hemoglobin >2 g/dL over a 24-hour period, or bleeding leading to transfusion of two or more units of whole blood or red blood cells, or intracranial bleeding events.

Randomization to 48 hours after anticoagulation cessation, approximately 5-7 days post-randomization
New coagulation events
Periodo de tiempo: Randomization to 48 hours after anticoagulation cessation, approximately 5-7 days post-randomization

Incidence of new coagulation events on anticoagulation, including thrombotic events and clinically relevant bleeding adverse events as defined in Outcomes 5 and 6.

Randomization to 48 hours after anticoagulation cessation, approximately 5-7 days post-randomization

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Benjamin Tillman, MD, Vanderbilt University Medical Center

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

26 de junio de 2024

Finalización primaria (Actual)

8 de septiembre de 2026

Finalización del estudio (Actual)

8 de septiembre de 2026

Fechas de registro del estudio

Enviado por primera vez

19 de marzo de 2024

Primero enviado que cumplió con los criterios de control de calidad

19 de marzo de 2024

Publicado por primera vez (Actual)

26 de marzo de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

21 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

15 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 232192

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Individual participant data that underlie the results reported will be made available (including data dictionaries) after de-identification.

Marco de tiempo para compartir IPD

The data will become available 3 months following publication of outcomes and will remain available for at least 5 years.

Criterios de acceso compartido de IPD

Data will be made available to researchers who provide a methodologically sound proposal that has been approved by the Vanderbilt Institutional Review Board and the study executive committee.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • CÓDIGO_ANALÍTICO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir